FARMASINTEZ, AO

Orchid Pharma Enters Russia Licensing Pact for Novel Antibiotic Exblifep, US Deal in Advanced Talks

- Orchid Pharma signed an exclusive licensing and supply agreement with Pharmasyntez JSC for Exblifep in Russia, with a potential revenue opportunity of $178 million over 10 years. - The company is in advanced discussions to out-license enmetazobactam in the United States, with a deal expected in the near term following FDA approval in February 2024. - Exblifep (cefepime/enmetazobactam) targets serious Gram-negative infections including cUTI and HAP/VAP, with lifetime global sales potential estimated at $1 billion to $2 billion. - Orchid is pursuing multi-region licensing deals across Japan, Latin America, and Southeast Asia, with at least half of these partnerships expected to be signed in the coming quarters.